title: Donepezil for Down's syndrome.
authors.forename: P S
authors.initials: PS
authors.lastname: Kishnani
authors.forename: G A
authors.initials: GA
authors.lastname: Spiridigliozzi
authors.forename: J H
authors.initials: JH
authors.lastname: Heller
authors.forename: J A
authors.initials: JA
authors.lastname: Sullivan
authors.forename: P M
authors.initials: PM
authors.lastname: Doraiswamy
authors.forename: K R
authors.initials: KR
authors.lastname: Krishnan
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D004314:Down Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D004334:Drug Administration Schedule; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil